Kazia Therapeutics Limited

NasdaqCM:KZIA Stock Report

Market Cap: US$6.8m

Kazia Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Kazia Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth24.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

Jul 06

Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial

Jun 15

Enrollment gets underway in Kazia's mid-stage lymphoma study

Jun 07

Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer

Dec 10

Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study

Dec 09

Kazia stock +22% on positive paxalisib data in glioblastoma

Nov 18

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kazia Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:KZIA - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20230-16-13-13N/A
9/30/20230-18-14-14N/A
6/30/20230-20-15-15N/A
3/31/20230-23-18-18N/A
12/31/2022N/A-25-20-20N/A
9/30/20220-25-21-21N/A
6/30/20220-25-23-23N/A
3/31/20228-20-15-15N/A
12/31/202115-15-8-8N/A
9/30/202115-12-9-9N/A
6/30/202115-8-9-9N/A
3/31/20218-11-14-14N/A
12/31/20200-13-18-18N/A
9/30/20201-13-14-14N/A
6/30/20201-12-9-9N/A
3/31/20201-11-7-7N/A
12/31/20191-10-5-5N/A
9/30/20191-10-6-6N/A
6/30/20191-10-7-7N/A
3/31/20192-11-6-6N/A
12/31/20182-12-5-5N/A
9/30/20183-9-7-7N/A
6/30/20183-6-9-9N/A
3/31/20184-6-10-10N/A
12/31/20176-6-12-12N/A
9/30/20177-8N/A-12N/A
6/30/20179-11N/A-11N/A
3/31/20177-12N/A-12N/A
12/31/20165-12N/A-12N/A
9/30/20164-12N/A-12N/A
6/30/20163-12N/A-12N/A
3/31/20163-10N/A-12N/A
12/31/20153-9N/A-12N/A
9/30/20152-8N/A-9N/A
6/30/20152-7N/A-6N/A
3/31/20152-7N/A-5N/A
12/31/20142-7N/A-5N/A
9/30/20141-7N/A-5N/A
6/30/20140-7N/A-6N/A
3/31/20140-6N/A-5N/A
12/31/20131-5N/A-3N/A
9/30/20131-3N/A-6N/A
6/30/20131-2N/A-9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if KZIA's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if KZIA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if KZIA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if KZIA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if KZIA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KZIA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.